Navigation Links
Shire Presents Results of Five Lialda(R) (mesalamine) Analyses at ACG 2009 Annual Scientific Meeting
Date:10/26/2009

SAN DIEGO, Oct. 26 /PRNewswire-FirstCall/ -- Shire plc (LSE: SHP, Nasdaq: SHPGY), the global specialty biopharmaceutical company, presented the results of three 5-aminosalicylic acid (5-ASA) persistency analyses at ACG 2009 Annual Scientific Meeting, evaluating persistency of Lialda® (mesalamine), Asacol® (mesalamine), Pentasa® (mesalamine) (250mg and 500mg), balsalazide [combined results from generic balsalazide disodium and Colazal® (balsalazide disodium)], and Dipentum® (olsalazine sodium) (500mg). Additionally, on October 27, 2009, Shire will present results of a Lialda patient experience survey as well as the results of a study that evaluated the impact of oral 5-ASAs on all-cause health care utilization and costs among ulcerative colitis (UC) patients with active disease.

"Persistency plays a significant role in the management of UC, and this data shows us just how challenging adherence can be for UC patients," said Roger Adsett, senior vice president of Shire's GI business unit. "The results of the Lialda and 5-ASA persistency analyses will provide insights as to how UC patients manage their mesalamine prescription refills."

Lialda is an FDA-approved, once-daily oral medication for the induction of remission in patients with active, mild to moderate UC. The safety and effectiveness of Lialda beyond eight weeks have not been established.

Factors Affecting Persistence with Mesalamine Therapy: Results from a Large Pharmacy Database

Poster Presentation: October 25, 2009, San Diego Convention Center (#293)

Results of a long-term persistency analysis showed that after 18 months of treatment, 13 percent of Lialda patients (n=6,170) were persistent (continuing). Also, 5 percent of Asacol patients (n=25,887), 6 percent (250m
'/>"/>

SOURCE Shire plc
Copyright©2009 PR Newswire.
All rights reserved

Page: 1 2 3 4 5 6 7 8

Related medicine technology :

1. Shire Targets Fourth Quarter Filing of BLA for REPLAGAL(R) for Fabry Disease With U.S. FDA
2. Shire and Sandoz Settle all Pending Litigation Concerning ADDERALL XR(R)
3. Veriscrip and DAMMAD Team Up to Combat Prescription Drug Abuse in New Hampshire
4. New Hampshire Rx Card Launching Statewide
5. Shire Announces FDA Approval of Once-Daily INTUNIV(TM) (guanfacine) Extended Release Tablets for the Treatment of ADHD in Children and Adolescents Aged 6 to 17
6. Shire Completes Submission of NDA for Velaglucerase Alfa for Type 1 Gaucher Disease and Reports Positive Results for Remaining Two Phase III Trials
7. Shire Reports Positive Results From First of Three Phase III Trials of velaglucerase alfa for Type 1 Gaucher Disease and Provides Important Updates on Interactions With FDA
8. Shire Receives Fast Track Designation for velaglucerase alfa for Gaucher Disease
9. Shire has Filed a Treatment Protocol for Velaglucerase Alfa for Gaucher Disease
10. Shire Presented Results of a New Database Analysis on Lialda(R) (Mesalamine) and Other 5-ASAs for Ulcerative Colitis at Digestive Disease Week
11. Shire Announces Study Results of the Effects of INTUNIV(TM) (Guanfacine) Extended Release on Secondary Measures in Children with ADHD and Oppositional Symptoms
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:8/22/2014)... Aug. 22, 2014   Zacks Equity Research highlights Epizyme ... the Day and Panera (Nasdaq: PNRA - Free Report ) ... provides analysis on Amicus Therapeutics (Nasdaq: FOLD - Free Report ... (Nasdaq: SHPG - Free Report ). Here is ... of the Day : The biotech bull market ...
(Date:8/22/2014)... Research and Markets has announced the addition ... Report 2014" report to their offering. ... 2014 is a professional and in-depth study on the ... a focus on the Chinese situation. The report ... classifications, applications and industry chain structure. The particulate respirators ...
(Date:8/22/2014)... , Cali ., Aug. 22, 2014 ... Papillomavirus Conference shows that a therapy being developed by Hera ... two that cause 70 percent of all cervical cancer. ... blocked the replication of HPV-16, HPV-18 and HPV-11 cells, according ... Broker , Ph.D., who presented the findings at the ...
Breaking Medicine Technology:Epizyme, Panera, Amicus Therapeutics, Sanofi and Shire highlighted as Zacks Bull and Bear of the Day 2Epizyme, Panera, Amicus Therapeutics, Sanofi and Shire highlighted as Zacks Bull and Bear of the Day 3Epizyme, Panera, Amicus Therapeutics, Sanofi and Shire highlighted as Zacks Bull and Bear of the Day 4Epizyme, Panera, Amicus Therapeutics, Sanofi and Shire highlighted as Zacks Bull and Bear of the Day 5Epizyme, Panera, Amicus Therapeutics, Sanofi and Shire highlighted as Zacks Bull and Bear of the Day 6Global and Chinese Particulate Respirators Industry Report 2014 2Study shows Hera Therapeutics experimental compound shuts down human papillomavirus that causes most cervical cancer 2
... DIEGO, Jan. 31, 2011 Volcano Corporation (Nasdaq: ... of Massachusetts has issued a decision that ruled in ... Inc., and against LightLab Imaging, Inc., on all of ... 11-page decision also rejected LightLab,s request for injunctive relief. ...
... its continuing partnerships with Brazilian public health authorities and ... Mr. Nelson dos Santos as interim vice president of ... nonprofit organization whose mission is to improve the health ... programs that help ensure the quality, safety and benefit ...
Cached Medicine Technology:Massachusetts Court Rules in Favor of Volcano and Against St. Jude Medical Subsidiary in Trade Secrets Case 2New Interim Leadership for USP-Brazil 2
(Date:8/22/2014)... Key West Health & Beauty’s ( http://www.keywesthealthandbeauty.com ... anticipated study results of the 12 best and worst ... accompanying infographic on their website. It appears that the ... impact on the skin and contribute to many unwanted ... asked how they determined the results, founder and skin ...
(Date:8/22/2014)... Medical Oncology (ESMO), the leading pan-European organisation representing ... three outstanding individuals receiving the Society,s esteemed annual ... Bokemeyer, Heikki Joensuu and Peter Boyle on the ... Madrid, Spain. , Carsten Bokemeyer will receive the ... transition of cancer discovery into real benefit at ...
(Date:8/22/2014)... in Sweden provides insight on how the brain processes ... different sources and sides of the body, in order ... are presented in the journal Neuron , show ... various types of sensory information, with specialised functional roles ... the main input structure in the basal ganglia, and ...
(Date:8/22/2014)... Oncology (ESMO), the leading pan-European organisation representing medical ... outstanding individuals receiving the Society,s esteemed annual awards. ... Heikki Joensuu and Peter Boyle on the occasion ... Spain. , Carsten Bokemeyer will receive the ESMO ... of cancer discovery into real benefit at patient ...
(Date:8/22/2014)... air in American cities is getting safer to breathe, ... progress has been made in reducing levels of harmful ... said in a news release. Since 1990, there ... from human sources such as coal-fired plants, a 66 ... in lead, which harms brain development in children. ...
Breaking Medicine News(10 mins):Health News:Key West Health & Beauty Announces The 12 Best & Worst U.S. Cities For Skin Study 2Health News:ESMO honors outstanding oncology professionals 2Health News:ESMO honors outstanding oncology professionals 3Health News:The striatum acts as hub for multisensory integration 2Health News:ESMO honours outstanding oncology professionals 2Health News:ESMO honours outstanding oncology professionals 3Health News:Air in U.S. Cities Getting Cleaner, EPA Says 2
... food cravings and keeping them in check may be ... first six-month phase of the study provides new insights ... their role in weight control. ,Cravings are ... Susan Roberts, PhD, director of the USDA HNRCAs Energy ...
... typically graduate students hired to help undergrads with their ... expert Bernardo J. Carducci said social assistants, people ... and social skills, should become staples, as well. ... Research Institute at IU Southeast, are no different than ...
... industrial body recognizing the downward trend of access to quality ... reverse the situation- more money and a significant private-public partnership. ... Chambers of Commerce and Industry (FICCI), India needs to spend ... of achieving 'Health for all' is to be attained by ...
... is considered a healthy role model the world over, but ... land of the rising sun. ,Japan's health ministry estimates ... age of 40 is obese and experts have identified a ... ,"The everyday habits among the Japanese have become ...
... what boys lose in the process of circumcision turns ... penis. ,The long-term-health impact of neo-natal ... circumcision on sexual function in the adult male have ... recent study, by M. Sorrels and colleagues from the ...
... but they plan to add to their family in a big way ... Stewart inquired as to just how many kids Angelina wanted in all, ... as many as 14 little ones. ,"Hmm, it fluctuates between ... tewart then praised her by saying, "Wow, I'll tell you this: I ...
Cached Medicine News:Health News:Weight Management Achieved by Controlling and Not Suppressing Food Cravings 2Health News:Binge Drinking on College Campuses is a Matter of Fear, Not Freedom 2Health News:Binge Drinking on College Campuses is a Matter of Fear, Not Freedom 3Health News:FICCI Proposes Models To Solve Indias Healthcare Crisis 2Health News:Japanese are Weighed Down by Deviating from Their Traditional Diet 2
The Olympus continuous flow cystoscope was especially designed for laser treatment of the prostate and for collagen injection....
... Prostatron® System uses Cooled ... -TUMT®) to deliver precisely ... heat and destroy hyperplastic ... unique cooling mechanism simultaneously ...
... provides diagnostic testing in an easily ... a PCMCIA card,providing you diagnostic testing ... full-featured and performs all the,measurements performed ... to Office,Medic software for real-time data ...
... is a simple "1, 2, 3 ... compact with a streamline design It ... 13.5 lbs. It rapidly charges to ... full summary pre- & post-event documentation ...
Medicine Products: